ArticleFrontiers in drug safety and regulation2025
The role of MedDRA in global pharmacovigilance and public health during COVID-19: pandemic preparedness and response.
Article in Frontiers in drug safety and regulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has had a profound impact on global public health, infecting over 770 million individuals and resulting in more than 6.9 million deaths worldwide. In response, the rapid development of novel vaccines became critical to controlling the spread of the virus and safeguarding public health. The accelerated rollout of these vaccines required an expedited evaluation of their quality, efficacy, and safety. This article highlights the role of the Medical Dictionary for Regulatory Activities Maintenance and Support Services Organization (MedDRA MSSO) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), the terminology owner, in addressing the pandemic's challenges. The authors discuss MSSO's swift adaptation of its standard procedures to the pandemic's needs to develop and maintain MedDRA COVID-19 terms and tools. Through close collaboration with the ICH and expert working groups, the MSSO facilitated the development and timely updating of MedDRA terms and tools tailored to COVID-19, supporting global efforts in diagnosis, prognosis, and novel vaccine safety monitoring. The integration of these MedDRA terms and tools has been crucial in the timely reporting, coding, and analysis of adverse events following immunization (AEFIs), thereby facilitating public health responses worldwide and enabling the ongoing evaluation and safety assurance of COVID-19 vaccines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.